secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001493152-22-022608
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx reports Q2 2022 net loss of $2.6M; cash $10.8M; Phase 3 interim analysis expected Q4 2022
--------------------------------------------------------------------------------

- Net loss of $2.6M for Q2 2022 vs $1.3M in Q2 2021; R&D expense $1.4M vs $0.5M.
- Cash and equivalents and short-term marketable securities of $10.8M as of June 30, 2022.
- Phase 3 TIGeR-PaC first prospective interim analysis expected in Q4 2022.
- Protocol for Phase 2/3 trial in extrahepatic cholangiocarcinoma submitted to FDA; first patient enrollment planned Q4 2022.
- Appointed James Ahlers as CFO and Ron Kocak as VP & Controller in July 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315222022608/0001493152-22-022608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315222022608/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-022608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer